Satisfactory remission in a case of IgD myeloma: effectiveness of glucocorticoid treatment

Am J Hematol. 2001 Jan;66(1):62-3. doi: 10.1002/1096-8652(200101)66:1<62::AID-AJH1012>3.0.CO;2-#.

Abstract

IgD myeloma is an infrequent type of multiple myeloma and is characterized by an aggressive clinical behavior and a short survival time. No satisfactory treatments have thus far been established. Recently we treated a patient with IgD(lambda)-type myeloma with glucocorticoids, and succeeded in achieving a complete remission. This case seems to indicate a usefulness of glucocorticoid monotherapy for treating IgD myeloma.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Female
  • Glucocorticoids / administration & dosage
  • Glucocorticoids / therapeutic use*
  • Humans
  • Immunoglobulin D / blood*
  • Immunoglobulin lambda-Chains / blood*
  • Interferons / therapeutic use
  • Melphalan / administration & dosage
  • Methylprednisolone / administration & dosage
  • Middle Aged
  • Multiple Myeloma / blood
  • Multiple Myeloma / drug therapy*
  • Myeloma Proteins / analysis*
  • Nitrosourea Compounds / administration & dosage
  • Prednisolone / administration & dosage
  • Prednisolone / therapeutic use*
  • Remission Induction
  • Vincristine / administration & dosage

Substances

  • Glucocorticoids
  • Immunoglobulin D
  • Immunoglobulin lambda-Chains
  • Myeloma Proteins
  • Nitrosourea Compounds
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Interferons
  • Prednisolone
  • Melphalan
  • ranimustine
  • Methylprednisolone

Supplementary concepts

  • C-VAMP protocol